Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy?
Transitional Residency Program, Gundersen Lutheran Medical Center, La Crosse, Wisconsin, USA.
Julia S
JS
Lehman
Kurt K
KK
Mueller
Daniel F
DF
Schraith
D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D003622:Dapsone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005193:Family Planning Services / Q000379:methods*; D005260:Female; D005306:Fertilization / Q000187:drug effects*; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage*; D010392:Pemphigus / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011379:Prognosis; D012307:Risk Factors
D000890:Anti-Infective Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003622:Dapsone; D011241:Prednisone; D008727:Methotrexate